Smith+Nephew President of Orthopedics Skip Kiil touched on the company's strategy for ASCs during the third quarter earnings call, as transcribed by Seeking Alpha.
"The reality is we see the ambulatory care setting as a great strategic opportunity for Smith+Nephew," said Mr. Kiil. "If you look at the physical footprint of our robotics platform and where we're going with that, we obviously are performing very well in the ASC to date."
He didn't get into specifics about the company's growth profile in the ASC arena, but said it was "well north" of the industry average for organic business growth in other healthcare settings.
"Total joint reconstruction in the ASC setting really only makes up between 4 percent and 6 percent of the total procedure volume today," he said. "We see that expanding pretty substantially over the coming months and years for sure, and we'll participate willingly in that category."
Mr. Kiil also reported Navio sales were going well. "We have a great product and we've actually been converting quite a few accounts over the last few quarters and feel very strongly about the performance," he said. The company expects the next generation of products to become available next year.